On August 5, Insulet declined 23.5% in regular trading, trading at $127.51/share, with turnover of $65.54 million.

The selloff was triggered by the company lowering its full-year revenue guidance despite reporting Q2 results that exceeded expectations. Insulet posted Q2 adjusted EPS of $1.66, beating the consensus estimate of $1.45 by 14.5%, while revenue of $801.7 million surpassed the $787.2 million estimate, representing a 23.5% year-over-year increase. However, the simultaneous cut to full-year revenue outlook overshadowed the quarterly beat, fueling concerns over growth sustainability.

Regulatory headwinds compounded the negative sentiment. The FDA classified a recall of certain Omnipod pods as Class I — its most serious category — due to a cannula defect that could impair insulin delivery, with 24 serious injuries reported. The FDA also issued an early warning regarding potential high-risk issues with the company's insulin pump. UBS had downgraded Insulet to Neutral from Buy in late July, lowering its price target from $400 to $174.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)